• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    9/30/24 5:15:55 PM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email
    SC 13G/A 1 sc13ga.htm SC 13G/A



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    GRAIL, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001
    (Title of Class of Securities)
     
    384747101
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    Exhibit Index Found on Page 14
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM Opportunity Fund III, LP

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    397,435
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    397,435
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    397,435
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    1.28%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    PN
     
     
     
     
     
     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    2

     
    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM Opportunity Fund IV, LP

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Cayman Islands
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    626,080
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    626,080
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    626,080
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    2.01%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    PN
     
     
     
     

    *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.



    3



    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM Institutional Master Fund (BVI), Ltd.

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    862,371
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    862,371
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    862,371
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    2.78%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    OO
     
     
     
     

     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    4


    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM G SPV, LP

    I.R.S. Identification Nos. of above persons (entities only) 
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    1,588,000
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    1,588,000
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    1,588,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    5.11%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
     PN
     
     
     
     

     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.



    5




    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM LP

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    3,496,026
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    3,496,026
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    3,496,026
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    11.26%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IA
     
     
     
     

     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    6




    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM LLC

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    3,496,026
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    3,496,026
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    3,496,026
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    11.26%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    OO
     
     
     
     

     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    7



    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM Opportunity GP III LLC

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.

     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    397,435
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    397,435
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    397,435
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    1.28%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    OO
     
     
     
     

     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.



    8



    1
    NAMES OF REPORTING PERSONS
     
     
     
    CRCM Opportunity GP IV LLC

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    626,080
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    626,080
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    626,080
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    2.01%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    OO
     
     
     
     

     *
    The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.



    9




    1
    NAMES OF REPORTING PERSONS
     
     
     
    Chun R. Ding

    I.R.S. Identification Nos. of above persons (entities only)
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐ **The reporting persons making this filing hold an aggregate of 3,496,026 shares of Common Stock, which is 11.26% of the class of securities.
       
    (b)☑ **The reporting person on this cover page, however, may be deemed a beneficial owner only of the securities reported by it on this cover page.
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    St. Kitts & Nevis
     
     
     
     
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     

    3,496,026
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     
    3,496,026
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     

    3,496,026
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     

    11.26%*
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IN
     
     
     
     

     *
     The denominator for this calculation is based on 31,049,148 shares of Common Stock outstanding as of August 11, 2024, as reported in the Company’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 13, 2024.


    10


    Item 1.
    (a) Name of Issuer:  GRAIL, Inc. (the “Company”)
    (b) Address of Issuer’s Principal Executive Offices: 1525 O’Brien Drive, Menlo Park, CA 94025.

    Item 2.
    (a) Name of Person Filing:
    This statement is jointly filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting Persons.”
    (i)
    CRCM Opportunity Fund III, LP, a Cayman Islands exempted limited partnership (“CRCM Opportunity III”);
    (ii)
    CRCM Opportunity Fund IV, LP, a Cayman Islands exempted limited partnership (“CRCM Opportunity IV”);

    (iii)
    CRCM Institutional Master Fund (BVI), Ltd., a British Virgin Islands limited company (“CRCM Master Fund”);

    (iv)
    CRCM G SPV, LP, a Delaware limited partnership (“CRCM G SPV”);

    (v)
    CRCM LP, a Delaware limited partnership and the investment manager (“Investment Manager”) of CRCM Opportunity III, CRCM Opportunity IV, CRCM G SPV, LP and CRCM Master Fund (collectively, the “CRCM Funds”) and separately managed account clients (the “Managed Accounts”);

    (vi)
    CRCM LLC, a Delaware limited liability company and the general partner (the “General Partner”) of the Investment Manager, with respect to the  shares held by the CRCM Funds and the Managed Accounts;

    (vii)
    CRCM Opportunity GP III LLC, a Delaware limited liability company (“Opp III GP”) and the general partner of CRCM Opportunity III;

    (viii)
    CRCM Opportunity GP IV LLC, a Delaware limited liability company (“Opp IV GP”) and the general partner of CRCM Opportunity IV; and

    (ix)
    Chun R. Ding (“Ding”), is a citizen of St. Kits and Nevis and the managing partner of the Investment Manager, the manager of the General Partner, with respect to the shares held by the CRCM Funds and the Managed Accounts.

    (b) Address of Principal Business Office or, if none, Residence:
    The address of the principal business of (i-iv) CRCM Funds is 475 Sansome Street, Suite 730, San Francisco, CA 94111; (v-ix) the Investment Manager, the General Partner, Opp III GP, Opp IV GP, and Mr. Ding (c/o CRCM) is 475 Sansome Street, Suite 730, San Francisco, CA 94111.

    (c) Citizenship:
    The citizenship of each Reporting Person is set forth above.
    (d) Title and Class of Securities:  Common Stock, $0.001 par value (“Common Stock”).
    (e) CUSIP Number:  384747101



    11


    Item 3.  If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)
    ☐
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d1(b)(1)(ii)(F);
    (g)
    ☐
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813):
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    ☐
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4.  Ownership.
    The information required by Items 4(a) - (c) is set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.
     
    The shares of Common Stock reported hereby for the CRCM Funds are owned directly by the applicable fund.  The Investment Manager, as investment manager of the CRCM Funds and the Managed Accounts, may be deemed to be the beneficial owner of all such shares owned by the CRCM Funds and the Managed Accounts.  The General Partner, as general partner of the Investment Manager, may be deemed to be the beneficial owner of all of such shares owned by the CRCM Funds and the Managed Accounts. Opp III GP and Opp IV GP, as the general partner of CRCM Opportunity III and CRCM Opportunity IV, respectfully, may be deemed to be the beneficial owner of all of the shares owned by the fund for which they serve as general partner. Mr. Ding, as managing partner of the Investment Manager, and manager of the General Partner with the power to exercise investment discretion, may be deemed to be the beneficial owner of all such shares owned by the CRCM Funds and the Managed Accounts.  Each of the Investment Manager, the General Partner, Opp III GP, Opp IV GP, and Mr. Ding hereby disclaims any beneficial ownership of any such shares.


    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.  ☐





    12


    Item 6.  Ownership of More than Five Percent on Behalf of Another Person:  Not appliable.

    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company: Not applicable.

    Item 8.  Identification and Classification of Members of the Group:  Not applicable.

    Item 9.  Notice of Dissolution of Group:  Not applicable.

    Item 10.  Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.



    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: September 30, 2024

     
     
    /s/ Kelvin Koo
     
     
    CRCM LLC,
    On its own behalf and as the General Partner of
    CRCM LP, and as the Investment Manager of
    CRCM G SPV, LP
    CRCM Institutional Master Fund (BVI), Ltd.
    CRCM Opportunity Fund III, LP
    CRCM Opportunity Fund IV, LP
    CRCM Opportunity GP III LLC
    CRCM Opportunity GP IV LLC

         
      By:  Kelvin Koo, Attorney-in-Fact for Chun R. Ding, Member  
         
      /s/ Kelvin Koo  
     
    By:  Kelvin Koo, Attorney-in-Fact for Chun R. Dung
     
     


    13





    Exhibit Index


    Exhibit 1 Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
     
     
    Exhibit 2
    Power of Attorney appointing Kelvin Koo as true and lawful attorney-in-fact for Chun Ding (previously filed)
     
     
     
     

     

















    14

    EXHIBIT 1
    to
    SCHEDULE 13G




    JOINT ACQUISITION STATEMENT
    PURSUANT TO SECTION 240.13d-1(k)
     
          The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

    Dated: September 30, 2024



     
     
    /s/ Kelvin Koo
     
     
    CRCM LLC,
    On its own behalf and as the General Partner of
    CRCM LP, and as the Investment Manager of
    CRCM G SPV, LP
    CRCM Institutional Master Fund (BVI), Ltd.
    CRCM Opportunity Fund III, LP
    CRCM Opportunity Fund IV, LP
    CRCM Opportunity GP III LLC
    CRCM Opportunity GP IV LLC

         
      By:  Kelvin Koo, Attorney-in-Fact for Chun R. Ding, Member  
         
      /s/ Kelvin Koo  
     
    By:  Kelvin Koo, Attorney-in-Fact for Chun R. Dung
     
     



    15
    Get the next $GRAL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    4/21/2025$32.00Buy
    Canaccord Genuity
    11/27/2024$16.00Equal-Weight
    Morgan Stanley
    11/15/2024Peer Perform
    Wolfe Research
    10/17/2024Neutral
    Guggenheim
    More analyst ratings

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRAIL to Present at Jefferies Global Healthcare Conference 2025

      MENLO PARK, Calif., May 21, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Jefferies Global Healthcare Conference 2025 in New York on Tuesday, June 4 at 11:40 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to

      5/21/25 4:05:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL and athenahealth Team Up to Offer Healthcare Providers Streamlined Ordering of GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test

      MENLO PARK, Calif., May 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced a new partnership with athenahealth, a leading provider of network-enabled software and services for healthcare practices and systems nationwide. This collaboration will integrate ordering of GRAIL's Galleri® multi-cancer early detection (MCED) test into athenaCoordinator Core, a service designed to help streamline laboratory order transmission and care coordination for healthcare facilities. The integration will be provided through athenaOne, athenahealth's leading cloud-based electronic health record (EHR) solution.

      5/12/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    SEC Filings

    See more
    • GRAIL Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - GRAIL, Inc. (0001699031) (Filer)

      5/16/25 4:05:53 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by GRAIL Inc.

      S-8 - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:21:27 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by GRAIL Inc.

      10-Q - GRAIL, Inc. (0001699031) (Filer)

      5/14/25 4:11:41 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/14/24 3:35:14 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by GRAIL Inc.

      SC 13G - GRAIL, Inc. (0001699031) (Subject)

      11/12/24 4:47:47 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

      SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

      9/30/24 6:42:39 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President Ofman Joshua J. sold $1,635,867 worth of shares (48,213 units at $33.93), decreasing direct ownership by 9% to 511,460 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 9:44:24 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Chief Financial Officer Freidin Aaron sold $1,396,220 worth of shares (41,150 units at $33.93), decreasing direct ownership by 12% to 294,020 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 8:46:25 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Chief Executive Officer Ragusa Robert P sold $3,190,608 worth of shares (94,035 units at $33.93), decreasing direct ownership by 11% to 734,627 units (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      5/5/25 8:44:41 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

      4 - GRAIL, Inc. (0001699031) (Issuer)

      10/10/24 7:45:32 PM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    See more
    • GRAIL Appoints Sarah Krevans to Board of Directors

      MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

      10/21/24 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GRAIL with a new price target

      Canaccord Genuity initiated coverage of GRAIL with a rating of Buy and set a new price target of $32.00

      4/21/25 8:38:45 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Morgan Stanley initiated coverage on GRAIL with a new price target

      Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00

      11/27/24 7:29:05 AM ET
      $GRAL
      Medical Specialities
      Health Care
    • Wolfe Research initiated coverage on GRAIL

      Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

      11/15/24 7:46:11 AM ET
      $GRAL
      Medical Specialities
      Health Care

    $GRAL
    Financials

    Live finance-specific insights

    See more
    • GRAIL Reports First Quarter 2025 Financial Results

      Q1 U.S. Galleri Revenue Grew 22% Year-Over-Year to $28.7 Million GRAIL Announces Positive Top-Line Results From the Prevalent Screening Round of the NHS-Galleri Trial Cash Position of $677.9 Million Provides Runway Into 2028 MENLO PARK, Calif., May 13, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter 2025. Total revenue in the first quarter was $31.8 million, representing 19% growth year over year, and Galleri revenue was $29.1 m

      5/13/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL to Announce First Quarter 2025 Financial Results

      MENLO PARK, Calif., April 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2025 following the close of market on Tuesday, May 13, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves

      4/29/25 4:01:00 PM ET
      $GRAL
      Medical Specialities
      Health Care
    • GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results

      Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business

      2/20/25 4:02:00 PM ET
      $GRAL
      Medical Specialities
      Health Care